JUN 06, 2019 10:45 AM PDT

Drug Regimen Improves Clinical Outcomes for Kidney Transplant Patients

WRITTEN BY: Nouran Amin

Recent preliminary clinical trial results indicate the immunosuppressive drug belatacept can safely and effectively treat kidney transplant patients without adverse long-term side effects of traditional immunosuppressive regimens. Belatacept was approved by the U.S. Food and Drug Administration in 2011 for the prevention of immune rejection in kidney transplant patients and is the modified form of another drug called abatacept which treats rheumatoid arthritis.

The clinical trial is known as the Belatacept Early Steroid Withdrawal Trial (BEST) represented a significant step forward in enhancing the quality of life for postoperative patients receiving kidney transplantation.

"In the BEST trial, we tried to achieve something that hadn't been done in transplantation: to eliminate the use of corticosteroids very early after surgery and at the same time avoid the toxicities associated with the cornerstone immunosuppressive medications that had been used for four decades," said principal investigator E. Steve Woodle, MD, William A. Altemeier Professor in Research Surgery at the UC College of Medicine and director of Solid Organ Transplantation for UC Health."We wanted to reduce the side effects and toxicities of these medications and make it easier for patients to tolerate their anti-rejection drugs, while achieving rejection rates that are reasonable, this work solved a vexing 40-year-old problem and represents a major step forward in the field of transplantation."

Findings of the two-year study did not utilize the long-term use of prednisone (a corticosteroid) or tacrolimus (a calcineurin inhibitor).

"The primary problem that has prevented elimination of corticosteroids and calcineurin inhibitors to date has been excessive rejection rates," stated Rita Alloway, PharmD, research professor of nephrology at the UC College of Medicine and director of Transplant Clinical Research at UC Health. "The BEST Trial demonstrates that rejection risk with the new belatacept-based regimens was increased somewhat, and the reduced side effects and long-term cardiovascular risk reduction are major potential advantages of these regimens for the future."

Learn more about rejection following transplantation:

The standard care of treatment for patients who receive a kidney transplant is a post-surgery regimen involving corticosteroid and calcineurin inhibitor (CNI) immunosuppressants. These drugs have long been known to help organ transplant patients survive but can result in kidney toxicity or cardiovascular damage.

"This CNI- and steroid-free [immunosuppressive] protocol is a promising step forward in minimizing toxicities and improving renal allograft function," noted the author of the study. "Longer-term observations will need to be continued."

Source: University of Cincinnati

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Promising Drug for Prostate Cancer
Using high-throughput screening methods, cancer researchers from the UK have identified some promising drug candidates to test thousands of molecules. Spec...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
DEC 12, 2019
Cell & Molecular Biology
DEC 12, 2019
New Insight Into Chronic Pain May Help Create Novel Therapeutics
Acute pain can progress to chronic pain, which can cause other problems including depression, loss of motivation and sensory dysfunction....
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Drug Seeks To Target Treatment-Resistant Epilepsy
Ever imagined a world where you cannot shower alone, drive by yourself, and even go to work in fear of having the next seizure that can incapacitate you? U...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
New Painkiller More Effective than Opioids Discovered in Mud
Researchers have discovered a new painkiller dubbed to be as effective as opioids, only minus their disadvantages, from a 16-year old mud sample found near...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
New Injection that Treats Peanut Allergy
Peanut allergies affect between 1 and 3% of the US population. Associated with a heightened risk of severe anaphylactic reactions, oral immunotherapy is th...
Loading Comments...